<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00586209</url>
  </required_header>
  <id_info>
    <org_study_id>10511-01RY</org_study_id>
    <nct_id>NCT00586209</nct_id>
  </id_info>
  <brief_title>L-Glutamine Therapy for Sickle Cell Anemia</brief_title>
  <official_title>A Phase II, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study of L Glutamine Therapy for Sickle Cell Anemia and Sickle ß0-Thalassemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Emmaus Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose is to evaluate the effect of L-glutamine therapy on exercise endurance&#xD;
      and breath by breath exercise response of sickle cell anemia patients&#xD;
&#xD;
      The secondary purpose is to assess the effect of L-glutamine on incidence of painful crises;&#xD;
      level of chronic pain, and amount of daily requirement for narcotics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II, prospective, randomized, double-blind, placebo-controlled,&#xD;
      parallel-group,study to evaluate the safety and efficacy of oral L-glutamine therapy for&#xD;
      patients with sickle cell anemia or sickle β°-thalassemia who are at least 18 years old with&#xD;
      focus on the aspect of exercise endurance. In this study, the patients will orally take&#xD;
      L-glutamine or placebo twice daily, and clinical and hematological parameters will be&#xD;
      monitored. The adverse events,especially those attributable to L-glutamine therapy, will also&#xD;
      be monitored.&#xD;
&#xD;
      The data obtained will be essential in understanding the role of L-glutamine in therapy for&#xD;
      sickle cell anemia and sickle β°-thalassemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inadequate clinical supplies and Emmaus business decision.&#xD;
  </why_stopped>
  <start_date type="Actual">February 6, 2004</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">August 27, 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of L-glutamine Therapy on Exercise Endurance of Sickle Cell Anemia Patients</measure>
    <time_frame>Baseline, Weeks 8 and 12</time_frame>
    <description>Exercise endurance will be examined at each visit. Change from baseline will be reported at weeks 8 and 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of L-glutamine Therapy on Breath by Breath Exercise of Sickle Cell Patients</measure>
    <time_frame>Baseline, Weeks 18 and 12</time_frame>
    <description>Breath by breath exercise will be examined at each visit. Change from baseline will be reported at weeks 8 and 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Oral L-glutamine on Incidence of Painful Crises</measure>
    <time_frame>From Week 0 through Week 12</time_frame>
    <description>Incidence of panful crises will be assessed at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Oral L-glutamine on Amount of Daily Requirement for Narcotics</measure>
    <time_frame>From Week 0 through Week 20</time_frame>
    <description>Amount of daily requirement for narcotics will assessed at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Oral L-glutamine on Level of Chronic Pain</measure>
    <time_frame>From Week 0 to Week 12</time_frame>
    <description>Level of chronic pain will be assessed at each visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Sickle Cell Anemia</condition>
  <condition>Thalassemia</condition>
  <arm_group>
    <arm_group_label>L-glutamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>L-glutamine group will be given at the following dosage:&#xD;
17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily &gt;66.7 at 15 g 2X daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin group will be given at the following dosage:&#xD;
17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily &gt;66.7 at 15 g 2X daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Glutamine</intervention_name>
    <description>L-Glutamine at: 5 g 2X daily (17-33.3 Kg) 10 g 2x daily (33.4-66.6 Kg) 15 g 2x daily (&gt;66.7 kg)</description>
    <arm_group_label>L-glutamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (75% Maltodextrin, 24.5 % Starch, 0.5% Tricalcium Phosphate) - given at the same dosage as L-glutamine</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be eligible to participate in the study, a patient must meet all of the following&#xD;
        inclusion criteria:&#xD;
&#xD;
          -  Patient is at least 18 years of age.&#xD;
&#xD;
          -  Patient has been diagnosed with sickle cell anemia or sickle ß0-thalassemia&#xD;
             (documented by hemoglobin electrophoresis).&#xD;
&#xD;
          -  Patient has had at least two episodes of painful crises within 12 months of the&#xD;
             screening visit.&#xD;
&#xD;
          -  If the patient has been treated with an anti-sickling agent within three months of the&#xD;
             screening visit, the therapy must have been continuous for at least three months with&#xD;
             the intent to continue for the next 14 months.&#xD;
&#xD;
          -  Patient or the patient's legally authorized representative has given written informed&#xD;
             consent.&#xD;
&#xD;
          -  If the patient is a female of child-bearing potential, she agrees to practice a&#xD;
             recognized form of birth control during the course of the study.&#xD;
&#xD;
          -  Patient is able to perform exercise tolerance test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        If the patient meets any of the following criteria, the patient must not be enrolled:&#xD;
&#xD;
          -  Patient has a significant medical condition that required hospitalization (other than&#xD;
             sickle painful crisis) within two months of the screening visit.&#xD;
&#xD;
          -  Patient has diabetes mellitus with untreated fasting blood sugar &gt;115 mg/dL.&#xD;
&#xD;
          -  Patient has prothrombin time International Normalized Ratio (INR) &gt; 2.0.&#xD;
&#xD;
          -  Patient has serum albumin &lt; 3.0 g/dl.&#xD;
&#xD;
          -  Patient has received any blood products within three weeks of the screening visit.&#xD;
&#xD;
          -  Patient has a history of uncontrolled liver disease or renal insufficiency.&#xD;
&#xD;
          -  Patient is pregnant or lactating.&#xD;
&#xD;
          -  Patient has been treated with an experimental anti-sickling medication/treatment&#xD;
             (except hydroxyurea) within 30 days of the screening visit.&#xD;
&#xD;
          -  Patient has been treated with an experimental drug within 30 days of the screening&#xD;
             visit.&#xD;
&#xD;
          -  There are factors that would, in the judgment of the investigator, make it difficult&#xD;
             for the patient to comply with the requirements of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yutaka Niihara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LaBiomed At Harbor-UCLA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LA Biomed at Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>January 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2008</study_first_posted>
  <results_first_submitted>September 21, 2020</results_first_submitted>
  <results_first_submitted_qc>February 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 2, 2021</results_first_posted>
  <disposition_first_submitted>August 27, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>August 27, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 2, 2020</disposition_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</investigator_affiliation>
    <investigator_full_name>yutaka niihara</investigator_full_name>
    <investigator_title>President, Emmaus Medical</investigator_title>
  </responsible_party>
  <keyword>sickle cell disease</keyword>
  <keyword>sickle cell anemia</keyword>
  <keyword>L-glutamine</keyword>
  <keyword>Sickle Cell Anemia (homozygous)</keyword>
  <keyword>Sickle β°-Thalassemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>L-glutamine</title>
          <description>L-glutamine group will be given at the following dosage:&#xD;
17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily &gt;66.7 at 15 g 2X daily&#xD;
L-Glutamine: L-Glutamine at: 5 g 2X daily (17-33.3 Kg) 10 g 2x daily (33.4-66.6 Kg) 15 g 2x daily (&gt;66.7 kg)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Maltodextrin group will be given at the following dosage:&#xD;
17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily &gt;66.7 at 15 g 2X daily&#xD;
Placebo: Placebo (75% Maltodextrin, 24.5 % Starch, 0.5% Tricalcium Phosphate) - given at the same dosage as L-glutamine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>L-glutamine</title>
          <description>L-glutamine group will be given at the following dosage:&#xD;
17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily &gt;66.7 at 15 g 2X daily&#xD;
L-Glutamine: L-Glutamine at: 5 g 2X daily (17-33.3 Kg) 10 g 2x daily (33.4-66.6 Kg) 15 g 2x daily (&gt;66.7 kg)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Maltodextrin group will be given at the following dosage:&#xD;
17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily &gt;66.7 at 15 g 2X daily&#xD;
Placebo: Placebo (75% Maltodextrin, 24.5 % Starch, 0.5% Tricalcium Phosphate) - given at the same dosage as L-glutamine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of L-glutamine Therapy on Exercise Endurance of Sickle Cell Anemia Patients</title>
        <description>Exercise endurance will be examined at each visit. Change from baseline will be reported at weeks 8 and 12</description>
        <time_frame>Baseline, Weeks 8 and 12</time_frame>
        <population>The study was terminated by the Sponsor's business decision prior to achieving the planned enrollment. Due to this the data was not collected and not analyzed. However safety data was collected and analyzed to gather data on the safety of L-glutamine in sickle cell patients.</population>
        <group_list>
          <group group_id="O1">
            <title>L-glutamine</title>
            <description>L-glutamine group will be given at the following dosage:&#xD;
17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily &gt;66.7 at 15 g 2X daily&#xD;
L-Glutamine: L-Glutamine at: 5 g 2X daily (17-33.3 Kg) 10 g 2x daily (33.4-66.6 Kg) 15 g 2x daily (&gt;66.7 kg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Maltodextrin group will be given at the following dosage:&#xD;
17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily &gt;66.7 at 15 g 2X daily&#xD;
Placebo: Placebo (75% Maltodextrin, 24.5 % Starch, 0.5% Tricalcium Phosphate) - given at the same dosage as L-glutamine</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of L-glutamine Therapy on Exercise Endurance of Sickle Cell Anemia Patients</title>
          <description>Exercise endurance will be examined at each visit. Change from baseline will be reported at weeks 8 and 12</description>
          <population>The study was terminated by the Sponsor's business decision prior to achieving the planned enrollment. Due to this the data was not collected and not analyzed. However safety data was collected and analyzed to gather data on the safety of L-glutamine in sickle cell patients.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of L-glutamine Therapy on Breath by Breath Exercise of Sickle Cell Patients</title>
        <description>Breath by breath exercise will be examined at each visit. Change from baseline will be reported at weeks 8 and 12</description>
        <time_frame>Baseline, Weeks 18 and 12</time_frame>
        <population>The study was terminated by the Sponsor's business decision prior to achieving the planned enrollment. Due to this the data was not collected and not analyzed. However safety data was collected and analyzed to gather data on the safety of L-glutamine in sickle cell patients.</population>
        <group_list>
          <group group_id="O1">
            <title>L-glutamine</title>
            <description>L-glutamine group will be given at the following dosage:&#xD;
17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily &gt;66.7 at 15 g 2X daily&#xD;
L-Glutamine: L-Glutamine at: 5 g 2X daily (17-33.3 Kg) 10 g 2x daily (33.4-66.6 Kg) 15 g 2x daily (&gt;66.7 kg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Maltodextrin group will be given at the following dosage:&#xD;
17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily &gt;66.7 at 15 g 2X daily&#xD;
Placebo: Placebo (75% Maltodextrin, 24.5 % Starch, 0.5% Tricalcium Phosphate) - given at the same dosage as L-glutamine</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of L-glutamine Therapy on Breath by Breath Exercise of Sickle Cell Patients</title>
          <description>Breath by breath exercise will be examined at each visit. Change from baseline will be reported at weeks 8 and 12</description>
          <population>The study was terminated by the Sponsor's business decision prior to achieving the planned enrollment. Due to this the data was not collected and not analyzed. However safety data was collected and analyzed to gather data on the safety of L-glutamine in sickle cell patients.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Oral L-glutamine on Incidence of Painful Crises</title>
        <description>Incidence of panful crises will be assessed at each visit.</description>
        <time_frame>From Week 0 through Week 12</time_frame>
        <population>The study was terminated by the Sponsor's business decision prior to achieving the planned enrollment. Due to this the data was not collected and not analyzed. However safety data was collected and analyzed to gather data on the safety of L-glutamine in sickle cell patients.</population>
        <group_list>
          <group group_id="O1">
            <title>L-glutamine</title>
            <description>L-glutamine group will be given at the following dosage:&#xD;
17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily &gt;66.7 at 15 g 2X daily&#xD;
L-Glutamine: L-Glutamine at: 5 g 2X daily (17-33.3 Kg) 10 g 2x daily (33.4-66.6 Kg) 15 g 2x daily (&gt;66.7 kg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Maltodextrin group will be given at the following dosage:&#xD;
17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily &gt;66.7 at 15 g 2X daily&#xD;
Placebo: Placebo (75% Maltodextrin, 24.5 % Starch, 0.5% Tricalcium Phosphate) - given at the same dosage as L-glutamine</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Oral L-glutamine on Incidence of Painful Crises</title>
          <description>Incidence of panful crises will be assessed at each visit.</description>
          <population>The study was terminated by the Sponsor's business decision prior to achieving the planned enrollment. Due to this the data was not collected and not analyzed. However safety data was collected and analyzed to gather data on the safety of L-glutamine in sickle cell patients.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Oral L-glutamine on Amount of Daily Requirement for Narcotics</title>
        <description>Amount of daily requirement for narcotics will assessed at each visit.</description>
        <time_frame>From Week 0 through Week 20</time_frame>
        <population>The study was terminated by the Sponsor's business decision prior to achieving the planned enrollment. Due to this the data was not collected and not analyzed. However safety data was collected and analyzed to gather data on the safety of L-glutamine in sickle cell patients.</population>
        <group_list>
          <group group_id="O1">
            <title>L-glutamine</title>
            <description>L-glutamine group will be given at the following dosage:&#xD;
17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily &gt;66.7 at 15 g 2X daily&#xD;
L-Glutamine: L-Glutamine at: 5 g 2X daily (17-33.3 Kg) 10 g 2x daily (33.4-66.6 Kg) 15 g 2x daily (&gt;66.7 kg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Maltodextrin group will be given at the following dosage:&#xD;
17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily &gt;66.7 at 15 g 2X daily&#xD;
Placebo: Placebo (75% Maltodextrin, 24.5 % Starch, 0.5% Tricalcium Phosphate) - given at the same dosage as L-glutamine</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Oral L-glutamine on Amount of Daily Requirement for Narcotics</title>
          <description>Amount of daily requirement for narcotics will assessed at each visit.</description>
          <population>The study was terminated by the Sponsor's business decision prior to achieving the planned enrollment. Due to this the data was not collected and not analyzed. However safety data was collected and analyzed to gather data on the safety of L-glutamine in sickle cell patients.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Oral L-glutamine on Level of Chronic Pain</title>
        <description>Level of chronic pain will be assessed at each visit.</description>
        <time_frame>From Week 0 to Week 12</time_frame>
        <population>The study was terminated by the Sponsor's business decision prior to achieving the planned enrollment. Due to this the data was not collected and not analyzed. However safety data was collected and analyzed to gather data on the safety of L-glutamine in sickle cell patients.</population>
        <group_list>
          <group group_id="O1">
            <title>L-glutamine</title>
            <description>L-glutamine group will be given at the following dosage:&#xD;
17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily &gt;66.7 at 15 g 2X daily&#xD;
L-Glutamine: L-Glutamine at: 5 g 2X daily (17-33.3 Kg) 10 g 2x daily (33.4-66.6 Kg) 15 g 2x daily (&gt;66.7 kg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Maltodextrin group will be given at the following dosage:&#xD;
17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily &gt;66.7 at 15 g 2X daily&#xD;
Placebo: Placebo (75% Maltodextrin, 24.5 % Starch, 0.5% Tricalcium Phosphate) - given at the same dosage as L-glutamine</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Oral L-glutamine on Level of Chronic Pain</title>
          <description>Level of chronic pain will be assessed at each visit.</description>
          <population>The study was terminated by the Sponsor's business decision prior to achieving the planned enrollment. Due to this the data was not collected and not analyzed. However safety data was collected and analyzed to gather data on the safety of L-glutamine in sickle cell patients.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected throughout the course of the study (53 weeks or about 1 year).</time_frame>
      <desc>The Safety population will include all patients who received at least one dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>L-glutamine</title>
          <description>L-glutamine group will be given at the following dosage:&#xD;
17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily &gt;66.7 at 15 g 2X daily&#xD;
L-Glutamine: L-Glutamine at: 5 g 2X daily (17-33.3 Kg) 10 g 2x daily (33.4-66.6 Kg) 15 g 2x daily (&gt;66.7 kg)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Maltodextrin group will be given at the following dosage:&#xD;
17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily &gt;66.7 at 15 g 2X daily&#xD;
Placebo: Placebo (75% Maltodextrin, 24.5 % Starch, 0.5% Tricalcium Phosphate) - given at the same dosage as L-glutamine</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (7.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Sickle cell anaemia with crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (7.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Sickle cell anaemia with crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Mouth Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Endodontic procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yutaka Niihara, MD, MPH</name_or_title>
      <organization>Emmaus Medical, Inc.</organization>
      <phone>310-214-0065</phone>
      <email>yniihara@emmausmedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

